Development

Articles

Lubrizol has launched Apisolex technology to improve solubility and simplify the manufacturing of parenteral drug products.

Lubrizol Launches Apisolex Technology 

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

With high-concentration biologics, careful selection of excipients in formulation is crucial for reducing viscosity without destabilizing the protein.

Developing Excipients for High-Concentration Biologic Formulations

Roquette is investing €25 million at its site in Lestrem, France to strengthen its position in the polyols market.

Roquette Invests €25 million for Polyols at its Site in Lestrem, France

Careful selection is essential for achieving viscosity reduction without protein destabilization.

Excipients for High-Concentration Biologics

Advances in technology are accelerating the development and manufacture of subunit vaccines, an established class of vaccines.

Subunit Vaccines and the Fight Against COVID-19

Contract manufacturers play a key role in the production of lipid nanoparticles for RNA vaccines.

Meeting the Demand for Lipid Excipients 

DFE’s new line will offer market purity and low endotoxin excipients for use in formulation, while providing drug developers and manufacturers high-quality excipient technology and services. 

DFE Pharma to Launch New Biopharma Excipient Solution 

The company will join the network of approved manufacturers of the lipid excipients. 

AMRI to Develop and Manufacture Lipid Excipients for Pfizer-BioNTech COVID-19 Vaccine

A newly developed polymer, DynaShield, may have the capability to ensure global access for COVID-19 treatment and prevention.

Helena Offers Polymer Solution to Global Cold Chain Issues for COVID-19 Vaccines, Biologics, and Therapeutics

With the acquisition, Evonik will expand its life science division and its portfolio of functional excipients and biomaterials. 